Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: Are these three gender specific determinants additive for overall men's heath and do they improve traditional non-gender specific determinants to lessen cardiovascular risk and all-cause mortality?

International Journal of Clinical Practice

Volumn 64, Issue 13, 2010, Pages 1754-1762

  Miner, M M ^a   Seftel, A D ^b  

^a BROWN UNIVERSITY   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ALBUMINURIA; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; DEPRESSION; DIABETIC PATIENT; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HEALTH STATUS; HUMAN; HYPERTENSION; HYPOGONADISM; INCIDENCE; MALE; MEN'S HEALTH; METABOLIC SYNDROME X; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEXUAL FUNCTION; SEXUAL HEALTH; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; RISK ASSESSMENT; TESTOSTERONE;

EID: 78649285240     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02521.x     Document Type: Review

References (64)

1. Gray LC, Newbury JW,. Health assessment of elderly patients. Aust Fam Physician 2004; 33: 795 - 7.
2. Xu J, Kochanek KD, Tejada-Vera B,. Deaths: preliminary data for 2007. Natl Vital Stat Rep 2009; 58: 1 - 51.
3. American Heart Association. Heart Disease and Stoke Statistics - 2009 Update. Dallas, Texas: American Heart Association, 2009.
4. Mendez-Luck CA, Yu H, Meng YY, Jhawar M, Wallace SP,. Over four million California adults age 45 and older have high blood pressure. Policy Brief UCLA Cent Health Policy Res 2004; 7: 1 - 8.
5. Biswas S, Dastidar DG, Roy KS, Pal SK, Biswas TK, Ganguly SB,. Complications of hypertension as encountered by primary care physician. J Indian Med Assoc 2003; 101: 257 - 9.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486 - 97.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7 - 22.
8. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149 - 58.
9. See R, Lindsey JB, Patel MJ, et al. Application of the screening for heart attack prevention and education task force recommendations to an urban population: observations from the Dallas Heart Study. Arch Intern Med 2008; 168: 1055 - 62.
10. Rosen R, Goldstein I, Heiman J, et al. The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. Int J Impot Res 1999; 11: 59 - 70, discussion 70.
11. American Urological Association. Prostate-Specific Antigen Best Practice Statement. Linthicum, MD: American Urological Association, 2009 Update.
12. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA,. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996 - 3002.
13. Vikan T, Schirmer H, Njølstad I, Svartberg J,. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol 2009; 161: 435 - 42.
14. Araujo AB, Kupelian V, Page ST, et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007; 167: 1252 - 60.
15. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694 - 701.
16. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR,. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660 - 5.
17. Seftel AD, Sun P, Swindle R,. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341 - 5.
18. Walczak MK, Lokhandwala N, Hodge MB, Guay AT,. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5: 19 - 24.
19. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z,. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123 - 6.
20. Chiurlia E, D'Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG,. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005; 46: 1503 - 6.
21. Yaman O, Gulpinar O, Hasan T, Ozdol C, Ertas FS, Ozgenci E,. Erectile dysfunction may predict coronary artery disease: relationship between coronary artery calcium scoring and erectile dysfunction severity. Int Urol Nephrol 2008; 40: 117 - 23.
22. Vlachopoulos C, Rokkas K, Ioakeimidis N, et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol 2005; 48: 996 - 1002.
23. Ward RP, Weiner J, Taillon LA, Ghani SN, Min JK, Williams KA,. Comparison of findings on stress myocardial perfusion imaging in men with versus without erectile dysfunction and without prior heart disease. Am J Cardiol 2008; 101: 502 - 5.
24. Min JK, Williams KA, Okwuosa TM, Bell GW, Panutich MS, Ward RP,. Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med 2006; 166: 201 - 6.
25. Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20: 92 - 9.
26. Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med 2009; 6: 2445 - 54.
27. Araujo AB, Hall SA, Ganz P, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol 2010; 55: 350 - 6.
28. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113: 791 - 8.
29. Marma AK, Berry JD, Ning H, et al. Distribution of 10-year lifetime predicted risks for cardiovascular disease in US adults: FINDINGS FROM the National Health and Nutrition Examination Survey 2003-2006. Circ Cardiovasc Qual Outcomes 2010; 3: 4 - 5.
30. Rosen RC, Jackson G, Kostis JB,. Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep 2006; 7: 490 - 6.
31. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108 - 13.
32. Heruti RJ, Steinvil A, Shochat T, et al. Screening for erectile dysfunction and associated cardiovascular risk factors in Israeli men. Isr Med Assoc J 2008; 10: 686 - 90.
33. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008; 51: 2045 - 50.
34. Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004; 364: 689 - 96.
35. Ridker PM, Danielson E, Fonseca FA, et al., on behalf of the JUPITER Study Group. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195 - 207.
36. Ma RC-W, So W-Y, Yang X, et al. Erectile dysfunction predicts coronary artery disease in type 2 diabetes. J Am Coll Cardiol 2008; 51: 2045 - 50.
37. Bohm M, Baumhakel M, Koon T, for the ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both. Circulation 2010; 121: 1439 - 46.
38. Miner MM,. Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events. Mayo Clin Proc 2009; 84: 102 - 4.
39. Ponholzer A, Temml C, Obermayr R, et al. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol 2005; 48: 512 - 8.
40. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
41. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR,. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672 - 6.
42. Oliveros RA, Zion AS, Rosenberg Y, Selvaraj CL, Chilton R,. Impaired fasting glucose as a treatment target in diabetes management. Curr Cardiol Rep 2009; 11: 460 - 7.
43. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008; 51: 264 - 70.
44. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640 - 5.
45. Ervin RB,. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; 13: 1 - 7.
46. Arnlöv J, Ingelsson E, Sundström J, Lind L,. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 184 - 7.
47. Wannamethee SG,. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes (Lond) 2008; 32 (Suppl. 2): S25 - 9.
48. Lorenzo C, Williams K, Hunt KJ, Haffner SM,. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8 - 13.
49. Wang CC, Chancellor MB, Lin JM, Hsieh JH, Yu HJ,. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years. BJU Int 2010; 105: 1136 - 40.
50. AlSaraj F, McDermott JH, Cawood T, et al. Prevalence of the metabolic syndrome in patients with diabetes mellitus. Ir J Med Sci 2009; 178: 309 - 13.
51. Dandona P, Dhindsa S, Chandel A, Chaudhuri A,. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med 2009; 121: 45 - 51.
52. Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care 2009; 32: 1049 - 51.
53. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB,. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843 - 50.
54. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036 - 41.
55. Haring R, Völzke H, Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009; 58: 2027 - 31.
56. Köhler TS, Kim J, Feia K, et al. Prevalence of androgen deficiency in men with erectile dysfunction. Urology 2008; 71: 693 - 7.
57. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31: 1494 - 501.
58. Qaseem A, Snow V, Demberg T, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American Colloge of Physicians. Ann Intern Med 2009; 151: 1 - 44.
59. Andriole GL, Crawford D, Grubb R, for the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310 - 9.
60. Schroder FH, Hugosson J, Roobol M, et al., for the ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European Study. N Engl J Med 2009; 360: 1320 - 8.
61. US Preventative Task Force. The Guide to Clinical Preventative Services Agency for Healthcare Research and Quality. Rockville, MD: US Preventative Task Force, 2009.
62. Corona G, Mannucci E, Forti G, Maggi M,. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009; 32: 587 - 98.
63. Shabsigh R, Arver S, Channer KS, et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 2008; 62: 791 - 8.
64. Jones TH, Saad F,. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009; 207: 318 - 27.